Medical Advocates
HIV Infection/Disease
 
Management of Lipodystrophy-
Related Disorders


General Reports
 Diagnostics
 Modification of ARV Therapy
 Drugs
Nutrition
 Surgery
Exercise
 Miscellaneous Agents
 Medication Adherence
 
HIV Lipodystrophy Main Page   Main New/Newsworthy Home Page  
Last Update: November 25, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
       Journal Papers, Abstracts, and Commentaries
 
 
Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
Sattler FR.
Top HIV Med. 2008 Oct-Nov;16(4):127-33.
 Abstract
 
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.
Brown TT.
J Clin Endocrinol Metab. 2008 Aug;93(8):2937-45.
 Abstract
 
HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS, Purdon SD, Hardman TC, et al
 Curr Med Res Opin. 2008 Jan 18
Abstract
 
Treatment options for lipodystrophy in HIV-positive patients.
Behrens GM. 
Expert Opin Pharmacother. 2008 Jan;9(1):39-52
 Abstract
 
Experience in the treatment of HIV-associated lipodystrophy.
Nelson L, Stewart KJ.
J Plast Reconstr Aesthet Surg. 2007 Nov 16;
 Abstract

Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of
HIV-Related Lipodystrophy.
Guaraldi G, Orlando G, Squillace N, et al
HIV Clin TrialsHIV Clin Trials. 2006 May-Jun;7(3):97-106.
Abstract

Diagnostics
 
        Journal Papers, Abstracts, and Commentaries
 
 
Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients.
Grima PF, Chiavaroli R, Grima P.
 Radiol Med. 2008 Oct 25.
Abstract
 
MRI of intra-abdominal fat and HIV-associated lipodystrophy: a case review.
Carlier R, De Truchis P, Ronze S, et al
J Radiol. 2007 Jul-Aug;88(7-8 Pt 1):947-56.
 Abstract
 
Association between Physical and Echographic Fat Thickness Assessments and a Lipodystrophy
Grading Scale in Lipodystrophic HIV Patients: Practical Implications.
Asensi V, Martin-Roces E, Collazos J, et al;
AIDS Res Hum Retroviruses. 2006 Sep;22(9):830-6.
Abstract
 
Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies
of HIV-Associated Lipodystrophy.
Smith DE, Hudson J, Martin A, et al.
HIV Clin Trials 2003 Jan-Feb;4(1):45-9
 Abstract
 
Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional
laser scans?Benn P, Ruff C, Cartledge J, et al.
HIV Med. 2003 Oct;4(4):325-331
 Abstract
 

CT appearances of HIV-related lipodystrophy syndrome.
Gellett LR, Haddon L, Maskell GF.
Br J Radiol 2001 Apr;74(880):382-3
 Abstract

     Conference Reports, Abstracts, and Posters
 
 
FDG-PET for early detection of lipodystrophy in HIV-infected patients
CP Bleeker-Rovers, B Zomer, P Koopmans
 (15IAC)
 Abstract

POSTER
Evaluation of Ultrasound for Assessing Facial Lipoatrophy in a Randomized,
Placebo-controlled Trial
D Carey, H Wand, A Martin, et al, et al.
(11 CROI)
 PDF Poster     Abstract

Modification of ARV Therapy
 

        Journal Papers, Abstracts, and Commentaries

  Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After
Switching from HAART to Trizivir Versus Continued HAART: The Trizal Study.
Lafeuillade A, Clumeck N, Mallolas J,
HIV Clin Trials 2003 Jan-Feb;4(1):37-43
 Abstract		  
 
Conference Reports, Abstracts, and Posters
 		    
 
Lipodystrophy in patients switched to indinavir/ritonavir 800/100mg bid and efavirenz
100mg bid and efavirenz 600mg qd after failing nucleoside combination therapy- 96
 week lipodystrophy outcomes in HIV-NAT 009
MA Boyd, D Bien, K Ruxrungtham
(15IAC)
 Abstract
 
Improvement of lipidic assestment and of lipodystrophy in HIV-experienced patients during
prolongued antiretroviral treatment interruption (PTI)
C Martinelli, R Giuntini, S Ambu, et al
 (15IAC)
 Abstract

POSTER
 Treatment with Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in
Subcutaneous Fat
C Cherry, M Gahan, S. Lewin, et al
 (9 CROI)
 PDF Poster  Abstract

POSTER
 A Randomised, Controlled, Open-Label Study of Revision of Antiretroviral Regimens
Containing Stavudine (d4T) and/or a Protease Inhibitor (PI) to Zidovudine
(ZDV)/Lamivudine (3TC)/Abacavir (ABC) to Prevent or Reverse Lipoatrophy: 48-Week
Data
 M John, I James, E McKinnon, et al.
(9 CROI)
 PDF Poster  Abstract

POSTER
 Improvements in Lipoatrophy (LA) Are Observed after 24 Weeks when Stavudine (d4T) Is
Replaced by Either Abacavir (ABC) or Zidovudine (ZDV)
G McComsey, T Lonergan, R Fisher, edt al.
 (9 CROI)
 PDF Poster  Abstract

POSTER
 Effect of Nucleoside (NRTI) Intensification on Prevalence of Morphologic Abnormalities
(MoAs) at Year 5 of Ritonavir (RTV) plus Saquinavir (SQV) Therapy in an HIV-Infected
Cohort
C Cohen, Y Shen, R Rode, DW Cameron, .et al
 (9 CROI)
 PDF Poster  Abstract

POSTER
 Atazanavir: A Once-Daily Protease Inhibitor with a Superior Lipid Profile: Results of
Clinical TrialsBeyond Week 48
P Piliero, P Cahn, G. Pantaleo, et al
(9 CROI)
 PDF Poster  Abstract

A Randomized Trial of Metabolic and Body Composition Changes in Patients
Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or
Nevirapine (NVP)
C Fisac, E Fumero, M Crespo,  et al.
 (9 CROI)
 Abstract

  

Nutritional Interventions
       

       Journal Papers, Abstracts, and Commentaries

 
A Randomized Clinical Trial to Evaluate the Effect of Diet on Quality of Life and Mood of
People Living With HIV and Lipodystrophy.
Reid C, Courtney M. 
J Assoc Nurses AIDS Care. 2007 Jul-Aug;18(4):3-11
 Abstract
 

Modifiable dietary habits and their relation to metabolic abnormalities in men and
women with human immunodeficiency virus infection and fat redistribution.
 Hadigan C, Jeste S, Anderson EJ, et al.
 Clin Infect Dis 2001 Sep 1;33(5):710-7
 Abstract

 

         Conference Reports, Abstracts, and Posters

  POSTER
The Effects of Caloric Restriction on the Hypermetabolism of HIV Lipodystrophy
L Kosmiski, S Stotz,  T Horton 
(13 CROI)
PDF Poster     Abstract
 
To document the prevalence of lipodystrophy in HIV positive patients and whether
dietary intervention can alter such effects
GW B Ng, PW Lung, MP Lee, et al
 (15IAC)
 Abstract

Effects of Niacin upon Fat Expansion in HIV-Positive Patients Who Have the Fat
Redistribution Syndrome (FRS)
J. Fesse , S Follansbee
(9 CROI)
 Abstract		  

Surgery
       
       Journal Papers, Abstracts, and Commentaries
 
 
Plastic surgical options for HIV-associated lipodystrophy.
Nelson L, Stewart KJ. 
J Plast Reconstr Aesthet Surg. 2007 Dec 20
Abstract

Surgical Algorithm for Management of HIV Lipodystrophy.
Davison SP, Timpone J Jr, Hannan CM.
 Plast Reconstr Surg. 2007 Dec;120(7):1843-58
 Abstract

Exercise
       
       Journal Papers, Abstracts, and Commentaries
 
  Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
 Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. 
Med Sci Sports Exerc. 2006 Mar;38(3):411-7.
 Abstract

Miscellaneous Agents
       
       Journal Papers, Abstracts, and Commentaries
 
 
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation:
a randomized controlled trial.
Lo J, You SM, Canavan B, et al
JAMA. 2008 Aug 6;300(5):509-19.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Prevalence of Complementary and Alternative Medicine Use Among HIV Patients for
Perceived Lipodystrophy.
Cho M, Ye X, Dobs A, Cofrancesco J.
 J Altern Complement Med. 2006 Jun;12(5):475-82.
 Abstract

Highly Purified 1000-cSt Silicone Oil for Treatment of Human Immunodeficiency
Virus-Associated Facial Lipoatrophy: An Open Pilot Trial.
Jones DH, Carruthers A, Orentreich D, et al 
Dermatol Surg. 2004 Oct;30(10):1279-86.
 Abstract

Medication Adherence
       
       Journal Papers, Abstracts, and Commentaries
 
  Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS.
 Corless IB, Kirksey KM, Kemppainen J 
AIDS Patient Care STDS. 2005 Sep;19(9):577-86.
 Abstract

HIV Lipodystrophy Main Page   Main New/Newsworthy Home Page  

Management of HIV-Associated
 Lipodystrophy-Related Disorders